All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Real-world use of blinatumomab in adult ALL
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The ALL Hub is pleased to present a visual abstract summarizing results from the NEUF study and other real-world studies assessing the efficacy of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia (B-ALL).
These studies confirmed the efficacy of blinatumomab in real-world patients with B-ALL, including measurable residual disease-positive patients, relapsed/refractory patients, patients in first and second complete remission, and newly diagnosed patients.1–3
1 vote - 85 days left
This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
- Boissel N, Chiaretti S, Papayannidis C, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: Results from the NEUF study. Blood Cancer J. 2023;13(1):2. DOI: 1038/s41408-022-00766-7
- Urbino I, Lengliné E, Rabian F, et al. Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission. Blood Adv. 2024;8(10):2405-2409. DOI: 1182/bloodadvances.2023012139
- Zhou H, Wu X, Yang Z, et al. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia. Invest New Drugs. 2024;42(3):299-308. DOI: 1007/s10637-024-01435-1
More about...
Your opinion matters
21 votes - 86 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox